Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 11:37:267-278.
doi: 10.1016/j.jare.2021.08.003. eCollection 2022 Mar.

Nicotinamide mononucleotide (NMN) as an anti-aging health product - Promises and safety concerns

Harshani Nadeeshani  1 , Jinyao Li  2 , Tianlei Ying  3 , Baohong Zhang  4 , Jun Lu  1   5   6   7   8   9   10
Affiliations
Review

Nicotinamide mononucleotide (NMN) as an anti-aging health product - Promises and safety concerns

Harshani Nadeeshani et al. J Adv Res. .

Abstract

Background: Elderly population has been progressively rising in the world, thus the demand for anti-aging heath products to assure longevity as well as to ameliorate age-related complications is also on the rise. Among various anti-aging health products, nicotinamide mononucleotide (NMN) has been gaining attentions of the consumers and the scientific community.

Aim of review: This article intends to provide an overview on the current knowledge on promises and safety concerns of NMN as an anti-aging health product.

Key scientific concepts of review: Nicotinamide adenine dinucleotide (NAD+) levels in the body deplete with aging and it is associated with downregulation of energy production in mitochondria, oxidative stress, DNA damage, cognitive impairment and inflammatory conditions. However, NMN, as the precursor of NAD+, can slow down this process by elevating NAD+ levels in the body. A number of in vivo studies have indicated affirmative results of therapeutic effects for various age-induced complications with NMN supplementation. One preclinical and one clinical study have been conducted to investigate the safety concerns of NMN administration while a few more human clinical trials are being conducted. As there is a large influx of NMN based anti-aging products on the market, proper clinical investigations are urgently needed to find out the effectiveness and safety of NMN supplementation.

Keywords: Age-induced diseases; Anti-aging; Nicotinamide adenine dinucleotide; Nicotinamide mononucleotide; Supplement.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

None
Graphical abstract
Fig. 1
Fig. 1
Percentage of global population aged 65 years or over according to the medium-variant projection (UN, 2019).
Fig. 2
Fig. 2
Chemical structure of nicotinamide mononucleotide (NMN).
Fig. 3
Fig. 3
NAD+ biosynthesis pathways in which NMN involves. Biosynthetic pathways of NAD+ in mammalian cells in which NMN involves are Preiss–Handler and salvage pathways, and the salvage pathway is the major source of NAD+. NAMPT-nicotinamide phosphoribosyltransferase; ATP-adenosine triphosphate; ADP-adenosine diphosphate; NMNAT-nicotinamide mononucleotide adenylyltransferase; NRK-nicotinamide riboside kinases; NAPRT-nicotinate phosphoribosyltransferase; NADS-nicotinamide adenine dinucleotide synthetases.
Fig. 4
Fig. 4
Causes for reducing NAD+ levels when aging and mechanism underlying anti-aging activity of NMN. DNA damage, chronic inflammation, oxidative stress and increasing NAD+ consuming enzymes (sirtuins, CD38/CD157, PARP, TNKS and BST) accelerate NAD degradation. The reduced levels of NAD+ cause downregulation of energy production in mitochondria, leading to aging and various age-associated diseases. NMN supplementation can reinstate NAD+ levels in the body through biosynthesis pathways, reversing the aging process and preventing age-associated diseases.
See this image and copyright information in PMC

References

    1. United Nations (UN), Department of Economic and Social Affairs, Population Division. World population ageing 2019: highlights (ST/ESA/SER.A/430). New York, USA: United Nations; 2019.
    1. Rea I.M., Gibson D.S., McGilligan V., McNerlan S.E., Alexander H.D., Ross O.A. Age and age-related diseases: role of inflammation triggers and cytokines. Front Immunol. 2018;9:586. - PMC - PubMed
    1. Diamanti-Kandarakis E., Dattilo M., Macut D., Duntas L., Gonos E.S., Goulis D.G., et al. Aging and anti-aging: a combo-endocrinology overview. Eur J Endocrinol. 2017;176:283–308. - PubMed
    1. Reisman N.R. Anti-aging medicine: the legal issues: legal issues associated with the current and future practice of anti-aging medicine. J Gerontol A Biol Sci Med Sci. 2004;59(7):B674–B681. - PubMed
    1. Yamamoto T., Byun J., Zhai P., Ikeda Y., Oka S., Sadoshima J. Nicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusion. PLoS ONE. 2014;9(6):e98972. - PMC - PubMed

Publication types